PT  - JOURNAL ARTICLE
AU  - Strikwerda-Brown, Cherie
AU  - Gonneaud, Julie
AU  - Hobbs, Diana A.
AU  - St-Onge, Frédéric
AU  - Binette, Alexa Pichet
AU  - Ozlen, Hazal
AU  - Provost, Karine
AU  - Soucy, Jean-Paul
AU  - Buckley, Rachel F.
AU  - Benzinger, Tammie L.S.
AU  - Morris, John C.
AU  - Villemagne, Victor L.
AU  - Doré, Vincent
AU  - Sperling, Reisa A.
AU  - Johnson, Keith A.
AU  - Rowe, Christopher C.
AU  - Gordon, Brian A.
AU  - Poirier, Judes
AU  - Breitner, John C.S.
AU  - Villeneuve, Sylvia
AU - the AIBL
AU - Knight ADRC
AU - HABS and PREVENT-AD research groups
TI  - AT(N) predicts near-term development of Alzheimer’s disease symptoms in unimpaired older adults
AID  - 10.1101/2022.05.09.22274638
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.05.09.22274638
4099  - http://medrxiv.org/content/early/2022/05/11/2022.05.09.22274638.short
4100  - http://medrxiv.org/content/early/2022/05/11/2022.05.09.22274638.full
AB  - Importance National Institute on Aging-Alzheimer’s Association (NIA-AA) workgroups have proposed biological research criteria intended to identify individuals with preclinical Alzheimer’s disease (AD).Objective Assess the clinical value of these biological criteria for prediction of near-term cognitive impairment in cognitively unimpaired older individuals.Design, Setting, and Participants We studied 580 cognitively unimpaired older adults from four independent cohorts (PREVENT-AD: 128; HABS: 153; AIBL: 48; Knight ADRC: 251) having ≥1 year of clinical observation following Aβ and tau PET (median follow-up: PREVENT-AD = 3.16 yrs [1.51-4.50]; HABS = 1.94yrs [1.13-5.42]; AIBL = 3.66yrs [1.72-5.98]); Knight ADRC = 3.01 yrs [1.04-6.20]).Exposures Based on binary assessment of global amyloid burden (A) and of a composite temporal region of tau PET uptake (T), we stratified participants into four groups (A+T+, A+T-, A-T+, A-T-). Presence (+) or absence (-) of neurodegeneration (N) was assessed using temporal cortical thickness.Main Outcomes and Measures We analyzed each cohort separately. Primary outcome was clinical progression to mild cognitive impairment (MCI). A secondary outcome was cognitive decline. We compared MCI progression and cognitive decline across the four biomarker groups. MCI was identified by consensus committee review in PREVENT-AD, HABS, and AIBL, and by a CDR ≥ 0.5 in Knight ADRC. Clinical raters were blinded to imaging, genetic, and fluid biomarker data. Using a composite measure, cognitive decline was identified by a slope >1 SD below that of A-T- ‘non-progressors’.Results Across cohorts, 32 - 83% of A+T+ participants progressed to MCI during follow-up (mean progression time 2.0 - 2.72 years), as compared with <12% of participants in other biomarker groups. In two cohorts, progression increased to 100% when A+T+ individuals were also (N+). Cox proportional hazard ratios for progression to MCI in the A+T+ group vs. other biomarker groups were >5. Many A+T+ ‘non-progressors’ nonetheless showed longitudinal cognitive decline, while cognitive trajectories in other groups remained predominantly stable.Conclusions and Relevance Clinical prognostic value of the NIA-AA research criteria was confirmed in four independent cohorts, with nearly all A+T+(N+) cognitively unimpaired older individuals developing AD symptoms within ∼2-3 years.Question What is the clinical relevance of the AT(N) biological classification of Alzheimer’s disease (AD) in unimpaired older adults?Findings In this prospective study of 580 cognitively unimpaired participants from four independent cohorts, between 31.58 and 100% of A+T+(N+) participants progressed to mild cognitive impairment (MCI) within 2-3 years after PET. The majority of A+T+ non-progressors also showed cognitive decline.Meaning Cognitively unimpaired older adults with biological AD are at imminent risk of developing MCI. These individuals may be ideal candidates for disease modifying therapies.Competing Interest StatementCSB is supported by a joint Postdoctoral Fellowship from Canadian Institutes of Health Research (CIHR), Alzheimer's Society of Canada (ASC), and Fonds de recherche du Quebec Sante. FS is supported by the Canada First Research Excellence Fund and Fonds de recherche du Quebec, awarded to the Healthy Brains, Healthy Lives initiative at McGill University. APB is supported by a Brightfocus Foundation Postdoctoral Fellowship. JPS receives fees from Biogen Canada and is involved in pro bono projects with Optina Diagnostics. RFB is supported by a K99/R00 award from the National Institute of Aging (R00AG061238-03) and an Alzheimer's Association Research Fellowship (AARF- 20-675646). JCM is supported by the National Institute of Health (NIH). VLV reports grants from Life Molecular Imaging, Avid Radiopharmaceuticals, and General Electric Healthcare. RAS and KAJ are involved in public-private partnership clinical trials sponsored by the NIH and Eli Lilly, which owns the distribution rights to flortaucipir, but they do not have any personal financial relationship with Eli Lilly. CCR has received speaker fees from Nutricia, Biogen and Roche, Scientific Advisory Board fees from Cerveau Technology and Prothena, payment for preparation of educational materials from Biogen and grants to his institution from Cerveau Technologies, Biogen, Abbvie, Actinogen and Eisai and Australian Government support from NHMRC grants APP1011689, APP10475151, APP1071430. BAG is supported by the Alzheimer's Association and NIH. SV is supported by a Canada Research Chair and a Canada Fund for Innovation grant. The PREVENT-AD was funded by CIHR, Alzheimer's Association, ASC, Brain Canada, McGill University, the government of Canada, an unrestricted gift from Pfizer Canada, the Canada Fund for Innovation, the Douglas Hospital Research Centre, and the Levesque Foundation, and Genome Quebec Innovation Center. Funding sources had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication. Funding StatementCSB is supported by a joint Postdoctoral Fellowship from Canadian Institutes of Health Research (CIHR), Alzheimer's Society of Canada (ASC), and Fonds de recherche du Quebec Sante. FS is supported by the Canada First Research Excellence Fund and Fonds de recherche du Quebec, awarded to the Healthy Brains, Healthy Lives initiative at McGill University. APB is supported by a Brightfocus Foundation Postdoctoral Fellowship. JPS receives fees from Biogen Canada and is involved in pro bono projects with Optina Diagnostics. RFB is supported by a K99/R00 award from the National Institute of Aging (R00AG061238-03) and an Alzheimer's Association Research Fellowship (AARF- 20-675646). JCM is supported by the National Institute of Health (NIH). VLV reports grants from Life Molecular Imaging, Avid Radiopharmaceuticals, and General Electric Healthcare. RAS and KAJ are involved in public-private partnership clinical trials sponsored by the NIH and Eli Lilly, which owns the distribution rights to flortaucipir, but they do not have any personal financial relationship with Eli Lilly. CCR has received speaker fees from Nutricia, Biogen and Roche, Scientific Advisory Board fees from Cerveau Technology and Prothena, payment for preparation of educational materials from Biogen and grants to his institution from Cerveau Technologies, Biogen, Abbvie, Actinogen and Eisai and Australian Government support from NHMRC grants APP1011689, APP10475151, APP1071430. BAG is supported by the Alzheimer's Association and NIH. SV is supported by a Canada Research Chair and a Canada Fund for Innovation grant. The PREVENT-AD was funded by CIHR, Alzheimer's Association, ASC, Brain Canada, McGill University, the government of Canada, an unrestricted gift from Pfizer Canada, the Canada Fund for Innovation, the Douglas Hospital Research Centre, and the Levesque Foundation, and Genome Quebec Innovation Center. Funding sources had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The following ethics committees gave ethical approval for this work: Institutional Review Board of McGill University; Partners Healthcare Institutional Review Board; Austin Health, St-Vincent's Health, Hollywood Private Hospital and Edith Cowan University; Washington University in St. Louis Institutional Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors